In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.
Photodynamic therapy combined with immunotherapy: Recent advances
JFB, Free Full-Text
T cells in health and disease Signal Transduction and Targeted
PDF) Immunotherapy in prostate cancer: current state and future
Frontiers T Cell Dysfunction and Exhaustion in Cancer
Neoantigen responses, immune correlates, and favorable outcomes
Nanomedicine for advanced cancer immunotherapy - ScienceDirect
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Cancers, Free Full-Text
